-continued

<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 100

aaataccctt acatccataa 20

<210> SEQ ID NO 101
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 101

acccttacat ccataat 17

<210> SEQ ID NO 102
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 102

ccttacatcc ataatcat 18

<210> SEQ ID NO 103
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 103

cttacatcca taatcattt 19

1. An antisense oligonucleotide, 10-30 nucleotides in length, wherein said antisense oligonucleotide comprises a contiguous nucleotide sequence 10-30 nucleotides in length, wherein the contiguous nucleotide sequence is at least 90% complementary, such as fully complementary to SEQ ID NO 1, wherein the antisense oligonucleotide is capable of inhibiting the expression of human TIA1 in a cell which is expressing human TIA1; or a pharmaceutically acceptable salt thereof.

2. The antisense oligonucleotide according to claim **1**, wherein the contiguous nucleotide sequence is at least 90% complementary, such as fully complementary to a sequence selected from the group consisting of SEQ ID NO 4-53.

3. The antisense oligonucleotide according to any one of claims **1** to **3**, wherein the contiguous nucleotide sequence is fully complementary to a region of SEQ ID NO 1, selected from the group consisting of the regions in list A.

4. The antisense oligonucleotide according to any one of claims **1** to **3**, wherein the contiguous nucleotide sequence is fully complementary to a region of SEQ ID NO 1, selected from the group consisting of the regions in list B.

5. The antisense oligonucleotide according to any one of claims **1-4**, wherein the antisense oligonucleotide is a gapmer oligonucleotide comprising a contiguous nucleotide sequence of formula 5'-F-G-F'-3', where region F and F' independently comprise 1-8 sugar modified nucleosides, and G is a region between 5 and 16 nucleosides which are capable of recruiting RNaseH.

6. The antisense oligonucleotide according to claim **5**, wherein the sugar modified nucleosides of region F and F' are independently selected from the group consisting of 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA, 2'-amino-DNA, 2'-fluoro-DNA, arabino nucleic acid (ANA), 2'-fluoro-ANA and LNA nucleosides.

7. The antisense oligonucleotide according to claim **5** or **6**, wherein region G comprises 5-16 contiguous DNA nucleosides.

8. The antisense oligonucleotide according to any one of claims **1-7**, wherein the antisense oligonucleotide is a LNA gapmer oligonucleotide.

9. The antisense oligonucleotide according to any one of claims **5-8**, wherein the LNA nucleosides are beta-D-oxy LNA nucleosides.

10. The antisense oligonucleotide according to any one of claims **1-9**, wherein the internucleoside linkages between the contiguous nucleotide sequence are phosphorothioate internucleoside linkages.

11. The antisense oligonucleotide according to any one of claims **1-10**, wherein the oligonucleotide comprises a contiguous nucleotide sequence selected from the group consisting of: 54-103.